SCHEMBL10106339

SCHEMBL10106339

COc1ccc(C=O)cc1C(c1cccc(Cl)c1)c1cc(C=O)ccc1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.47
TSHR P16473 1/20 0.47
AOX1 Q06278 1/20 0.44
TTR P02766 2/20 0.43
CYP1A2 P05177 2/20 0.42
FDPS P14324 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
HPGD P15428 3/20 0.41
TRIM24 O15164 1/20 0.41
ALDH5A1 P51649 1/20 0.41
ABAT P80404 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
TRIM33 Q9UPN9 1/20 0.41
MAPT P10636 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
LMNA P02545 1/20 0.40
RELA Q04206 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10106350 0.85 ALDH1A1 (0.54) ALDH1A1TSHRAOX1TTRFDPS
SCHEMBL10106328 0.85 ALDH1A1 (0.49) ALDH1A1TSHRAOX1TTRCYP1A2
SCHEMBL7074229 0.84 TTR (0.55) ALDH1A1TSHRAOX1TTRCYP1A2
SCHEMBL10106384 0.82 ALDH1A1 (0.48) ALDH1A1TSHRAOX1TTRCYP1A2
SCHEMBL10106362 0.80 ALDH1A1 (0.46) ALDH1A1TSHRAOX1TTRCYP1A2
SCHEMBL10106344 0.79 RAB9A (0.43) ALDH1A1TTRSMN1; SMN2HPGDTRIM24
SCHEMBL10106357 0.78 ALDH1A1 (0.45) ALDH1A1TSHRAOX1TTRCYP1A2
SCHEMBL7068044 0.77 ALDH1A1 (0.53) ALDH1A1TSHRAOX1TTRFDPS
SCHEMBL13179869 0.74 TTR (0.54) ALDH1A1TSHRAOX1TTRCYP1A2
SCHEMBL29405127 0.73 PDE4D (0.52) ALDH1A1TSHRAOX1TTRCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9321739-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2016-04-26 US disclosed
US-9321739-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2016-04-26 US disclosed
US-8119672-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2012-02-21 US disclosed
US-8119672-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2012-02-21 US disclosed
US-20110305666-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES RYS DAVID J (US) 2011-12-15 US disclosed
US-20110305666-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES RYS DAVID J (US) 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110305666-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES TTPA, HAVCR2, PML ALDH1A1 3369/4885TSHR 4829/4885AOX1 907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.